Clinical trial recruitment for ABBV-744 study Fundamentals Explained
In Section C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Individuals will acquire treatment till disease progression or maybe the participants are not able to tolerate the study drugs.88 These preclinical studies present paradigms for future clinical trials in AML, and th